Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
39 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the BioCryst Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of BioCryst Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of BioCryst Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of BioCryst Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the BioCryst Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate BioCryst Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of BioCryst Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the BioCryst Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of BioCryst Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioCryst Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of BioCryst Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 BioCryst Pharmaceuticals, Inc. Snapshot 5 BioCryst Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 BioCryst Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 BioCryst Pharmaceuticals, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 BioCryst Pharmaceuticals, Inc. - Pipeline Products Glance 12 BioCryst Pharmaceuticals, Inc. - Late Stage Pipeline Products 12 Pre-Registration Products/Combination Treatment Modalities 12 BioCryst Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13 Phase II Products/Combination Treatment Modalities 13 BioCryst Pharmaceuticals, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 BioCryst Pharmaceuticals, Inc. - Drug Profiles 15 peramivir 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 BCX-4161 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ulodesine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 BCX-4430 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Second Generation Plasma Kallikrein Inhibitor 1 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 BioCryst Pharmaceuticals, Inc. - Pipeline Analysis 23 BioCryst Pharmaceuticals, Inc. - Pipeline Products by Target 23 BioCryst Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 24 BioCryst Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 25 BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 26 BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates 27 BioCryst Pharmaceuticals, Inc. - Dormant Projects 32 BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 BCX-5191 33 peldesine 33 BioCryst Pharmaceuticals, Inc. - Company Statement 34 BioCryst Pharmaceuticals, Inc. - Locations And Subsidiaries 37 Head Office 37 Other Locations & Subsidiaries 37 Appendix 38 Methodology 38 Coverage 38 Secondary Research 38 Primary Research 38 Expert Panel Validation 38 Contact Us 39 Disclaimer 39
List of Tables BioCryst Pharmaceuticals, Inc., Key Information 5 BioCryst Pharmaceuticals, Inc., Key Facts 5 BioCryst Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7 BioCryst Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 8 BioCryst Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 9 BioCryst Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2014 10 BioCryst Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 11 BioCryst Pharmaceuticals, Inc. - Pre-Registration, 2014 12 BioCryst Pharmaceuticals, Inc. - Phase II, 2014 13 BioCryst Pharmaceuticals, Inc. - Preclinical, 2014 14 BioCryst Pharmaceuticals, Inc. - Pipeline by Target, 2014 23 BioCryst Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 24 BioCryst Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 25 BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 26 BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 27 BioCryst Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 32 BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 33 BioCryst Pharmaceuticals, Inc., Other Locations 37 BioCryst Pharmaceuticals, Inc., Subsidiaries 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.